Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02299635 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02299635 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 19 participants.
The verdict
NCT02299635, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)
Interventions
- DRUG PF-03084014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-02-03 |
| Est. Completion | 2016-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02299635
The ClinicalTrials.gov registry entry for NCT02299635 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-03084014 is the first listed.
NCT02299635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02299635 about?
NCT02299635 is a clinical study titled "A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations". This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smalle...
What is the current status of trial NCT02299635?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2015-02-03. Estimated completion is 2016-01-14.
What interventions are being tested in trial NCT02299635?
The interventions under investigation include: PF-03084014 (DRUG).
Who is sponsoring clinical trial NCT02299635?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.